| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.DNAREP.2006.05.031 |
| P698 | PubMed publication ID | 16857431 |
| P50 | author | Neil Osheroff | Q88626020 |
| P2093 | author name string | Carolyn A Felix | |
| Christos P Kolaris | |||
| P433 | issue | 9-10 | |
| P304 | page(s) | 1093-1108 | |
| P577 | publication date | 2006-07-20 | |
| P1433 | published in | DNA Repair | Q3894086 |
| P1476 | title | Topoisomerase II and the etiology of chromosomal translocations | |
| P478 | volume | 5 |
| Q24627296 | (-)-Epigallocatechin gallate, a major constituent of green tea, poisons human type II topoisomerases |
| Q38720721 | A Dual Topoisomerase Inhibitor of Intense Pro-Apoptotic and Antileukemic Nature for Cancer Treatment |
| Q33638364 | A diazirine-based photoaffinity etoposide probe for labeling topoisomerase II. |
| Q36858240 | A role for topoisomerase II alpha in the formation of radiation-induced chromatid breaks |
| Q46215182 | AML1/RUNX1 gene point mutations in childhood myeloid malignancies |
| Q33737465 | ATM modulates the loading of recombination proteins onto a chromosomal translocation breakpoint hotspot |
| Q58481811 | Acute Myeloid Leukemia |
| Q35995227 | An insertional mutagenesis screen identifies genes that cooperate with Mll-AF9 in a murine leukemogenesis model |
| Q34339160 | Autoantibodies to Tumor-Associated Antigens in Breast Carcinoma |
| Q24627367 | Bioflavonoids as poisons of human topoisomerase II alpha and II beta |
| Q89842982 | Bioflavonoids cause DNA double-strand breaks and chromosomal translocations through topoisomerase II-dependent and -independent mechanisms |
| Q58616150 | Bioflavonoids promote stable translocations between MLL-AF9 breakpoint cluster regions independent of normal chromosomal context: Model system to screen environmental risks |
| Q34379629 | Catalytic core of human topoisomerase IIα: insights into enzyme-DNA interactions and drug mechanism |
| Q38679992 | Chemical exposure and infant leukaemia: development of an adverse outcome pathway (AOP) for aetiology and risk assessment research |
| Q34601806 | Chromosomal rearrangements leading to MLL gene fusions: clinical and biological aspects |
| Q49977881 | Coupling the core of the anticancer drug etoposide to an oligonucleotide induces topoisomerase II-mediated cleavage at specific DNA sequences |
| Q92543190 | DNA Double Strand Breaks and Chromosomal Translocations Induced by DNA Topoisomerase II |
| Q37098901 | DNA Topology and Topoisomerases: Teaching a "Knotty" Subject |
| Q36903197 | DNA topoisomerase II, genotoxicity, and cancer |
| Q28284744 | DNA topoisomerases and their poisoning by anticancer and antibacterial drugs |
| Q37802740 | Deleterious Effects of Reactive Metabolites |
| Q39713158 | Dietary factors and the risk for acute infant leukemia: evaluating the effects of cocoa-derived flavanols on DNA topoisomerase activity |
| Q24642324 | Dietary polyphenols as topoisomerase II poisons: B ring and C ring substituents determine the mechanism of enzyme-mediated DNA cleavage enhancement |
| Q27000099 | Drugging topoisomerases: lessons and challenges |
| Q89723258 | Endogenous topoisomerase II-mediated DNA breaks drive thymic cancer predisposition linked to ATM deficiency |
| Q39939254 | Etoposide quinone is a covalent poison of human topoisomerase IIβ. |
| Q35058862 | Etoposide quinone is a redox-dependent topoisomerase II poison |
| Q52969772 | Evaluation of genome damage in subjects occupationally exposed to possible carcinogens. |
| Q33597526 | Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia |
| Q35558059 | Geminin overexpression prevents the completion of topoisomerase IIα chromosome decatenation, leading to aneuploidy in human mammary epithelial cells |
| Q38708591 | Genome-wide TOP2A DNA cleavage is biased toward translocated and highly transcribed loci |
| Q39552708 | Genotoxicity of dietary, environmental and therapeutic topoisomerase II poisons is uniformly correlated to prolongation of enzyme DNA residence |
| Q37867857 | Hydroquinone, a benzene metabolite, and leukemia: a case report and review of the literature |
| Q37008642 | Hydroquinone: an evaluation of the human risks from its carcinogenic and mutagenic properties |
| Q34909651 | Interactions between the etoposide derivative F14512 and human type II topoisomerases: implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage |
| Q33531510 | Mechanisms of chromosomal rearrangement in the human genome |
| Q37184342 | Mechanisms of leukemia translocations |
| Q83406998 | Microhomologies and topoisomerase II consensus sequences identified near the breakpoint junctions of the recurrent t(7;21)(p22;q22) translocation in acute myeloid leukemia |
| Q34198047 | Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis |
| Q37676681 | Molecular biology of therapy-related leukaemias |
| Q35560260 | Molecular pathogenesis of secondary acute promyelocytic leukemia |
| Q40138545 | Multipotent hematopoietic cells susceptible to alternative double-strand break repair pathways that promote genome rearrangements |
| Q33944673 | Mutation of cysteine residue 455 to alanine in human topoisomerase IIalpha confers hypersensitivity to quinones: enhancing DNA scission by closing the N-terminal protein gate |
| Q34701064 | Myeloperoxidase-dependent oxidation of etoposide in human myeloid progenitor CD34+ cells |
| Q34459467 | NPRL-Z-1, as a new topoisomerase II poison, induces cell apoptosis and ROS generation in human renal carcinoma cells |
| Q38682376 | Natural variation in a single amino acid substitution underlies physiological responses to topoisomerase II poisons |
| Q91604246 | Oncofetal HMGA2 attenuates genotoxic damage induced by topoisomerase II target compounds through the regulation of local DNA topology |
| Q36873293 | PARP1 is required for chromosomal translocations. |
| Q37658182 | Phytochemicals as Anticancer and Chemopreventive Topoisomerase II Poisons |
| Q56334908 | Polyamine-containing etoposide derivatives as poisons of human type II topoisomerases: Differential effects on topoisomerase IIα and IIβ |
| Q36508959 | Prospective tracing of MLL-FRYL clone with low MEIS1 expression from emergence during neuroblastoma treatment to diagnosis of myelodysplastic syndrome |
| Q53219322 | QS-ZYX-1-61 induces apoptosis through topoisomerase II in human non-small-cell lung cancer A549 cells. |
| Q48245703 | Quercetin alters the DNA damage response in human hematopoietic stem and progenitor cells via TopoII- and PI3K-dependent mechanisms synergizing in leukemogenic rearrangements. |
| Q37393189 | Rearrangements of the MLL gene are influenced by DNA secondary structure, potentially mediated by topoisomerase II binding. |
| Q43495742 | Salubrious effects of dexrazoxane against teniposide-induced DNA damage and programmed cell death in murine marrow cells |
| Q33417270 | Signatures of selection in fusion transcripts resulting from chromosomal translocations in human cancer |
| Q37332317 | Substituents on etoposide that interact with human topoisomerase IIalpha in the binary enzyme-drug complex: contributions to etoposide binding and activity. |
| Q39854226 | Suppression of topoisomerase IIalpha expression and function in human cells decreases chromosomal radiosensitivity. |
| Q27325200 | TDP2-dependent non-homologous end-joining protects against topoisomerase II-induced DNA breaks and genome instability in cells and in vivo |
| Q37108461 | The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing |
| Q28533804 | The broken MLL gene is frequently located outside the inherent chromosome territory in human lymphoid cells treated with DNA topoisomerase II poison etoposide |
| Q36944962 | The cellular etiology of chromosome translocations. |
| Q37061217 | The efficacy of topoisomerase II-targeted anticancer agents reflects the persistence of drug-induced cleavage complexes in cells |
| Q39044567 | The role of topoisomerase II beta on breakage and proximity of RUNX1 to partner alleles RUNX1T1 and EVI1. |
| Q33922870 | Topoisomerase II - drug interaction domains: identification of substituents on etoposide that interact with the enzyme. |
| Q37652882 | Topoisomerase II and leukemia |
| Q28475376 | Topoisomerase II-Mediated DNA Damage Is Differently Repaired during the Cell Cycle by Non-Homologous End Joining and Homologous Recombination |
| Q38360744 | Topoisomerase-mediated chromosomal break repair: an emerging player in many games |
| Q37323539 | Using 3'-bridging phosphorothiolates to isolate the forward DNA cleavage reaction of human topoisomerase IIalpha |
Search more.